Even though FAK inhibitors have demonstrated a high anti-tumor efficacy in some in vitro and mice xenograft models [55,61], the use of these inhibitors has shown lack of efficacy in early clinical trials on patients [62], suggesting an involvement of other yet unidentified pathways in favoring tumorigenesis. The gene discussed is PTK2; the disease is neoplasm.